Sep 29, 2025 · 30m · allin
Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Dave Ricks · 18m spoken Jason Calacanis · 4m spoken Chamath Palihapitiya · 2m spoken David Friedberg · 1m spoken David Sacks · 1s spoken
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
At the All-In Summit, Eli Lilly CEO Dave Ricks joins the panel to discuss the development, business strategy, and personal health impacts of GLP-1 weight-loss drugs. The discussion explores drug pricing, US manufacturing, public health policy, and the future of therapeutics in mental health and neurodegenerative disease.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. The hosts hold 30.7% of the talking time here. How this is scored →
The hosts as informed peer 3.8 Guest teaching 5.1 Guest disagreement 1.7 The hosts pushing back 2.7
speaking balance: gold is the hosts, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 8:44 Defending R&D margins against price cuts
Dave Ricks firmly rejects Calacanis's moral guilt-trip on drug prices, warning that slashing margins would snuff out economic incentives to fund future medical breakthroughs.
Hardest push from the hosts ▶ 22:03 Challenging guest on media capture via ad spendingJason Calacanis directly presses Ricks on whether massive TV ad budgets are spent intentionally to capture mainstream news media outlets.
Biggest teaching moment ▶ 14:50 Explaining US patent law shift and AI patent hackingDave Ricks provides a detailed explanation of the 2011 America Invents Act transition to first-to-file and how foreign competitors use AI algorithms to reverse-engineer non-infringing chemical derivatives.
The host holds their own ▶ 9:06 Friedberg probing capital allocation breakdownDavid Friedberg demonstrates corporate finance expertise by pressing Ricks on how Eli Lilly balances cash flow allocation across R&D, manufacturing capex, and share buybacks.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | The hosts as informed peer | Guest teaching | Guest disagreement | The hosts pushing back | Why |
|---|---|---|---|---|---|---|
| Eli Lilly Market Growth & CEO Highlights | 2 | 1 | 0 | 1 | The hosts welcome Eli Lilly CEO Dave Ricks with celebratory banter regarding personal weight loss on GLP-1 drugs. Chamath asks a broad introductory question about how Ricks decided to make an early strategic bet on this drug class. | |
| GLP-1 Development Timeline & Massive Financial Growth | 2 | 6 | 1 | 1 | Ricks outlines the 18-year timeline of GLP-1 development at Eli Lilly, detailing how an early Singapore study was halted when healthy volunteers lost weight too fast. The hosts ask basic informational questions regarding sales numbers and global user counts. | |
| Counterfeit Gray Markets & Off-Label Patient Experience | 3 | 2 | 1 | 3 | Chamath asks about Chinese gray market peptide synthesis and knockoffs. Calacanis shares his off-label prescription experience before setting up a moral question on drug pricing. | |
| Drug Pricing Deflation, Insurance Reimbursement & R&D Commitments | 4 | 6 | 3 | 4 | Ricks pushes back against Calacanis's moral framing by explaining that cutting prices too aggressively snuffs out the incentive to fund their $14.2B R&D pipeline. Friedberg demonstrates domain familiarity by asking about capital allocation tradeoffs between R&D, capex, and buybacks. | |
| Internal Innovation Challenges vs Venture Biotech | 5 | 7 | 3 | 3 | When Chamath asks if huge success creates a 'tragedy of riches' that stifles internal moonshots, Ricks rejects the premise, explaining that the real obstacle in big pharma is internal advancement friction rather than lack of big ideas. Ricks then schools the hosts on why biotech VC funding has collapsed into a 'dumpster fire'. | |
| Global Patent Laws, AI Reverse-Engineering & IP Risks | 4 | 7 | 2 | 2 | Friedberg probes international patent enforcement issues with China. Ricks explains the impact of the 2011 America Invents Act shift to first-to-file and how Chinese competitors use AI algorithms to reverse-engineer chemical structures just outside patent boundaries. | |
| Prophylactic GLP-1 Use, Healthspan & Biohacking Peptides | 4 | 5 | 1 | 2 | The hosts inquire about off-label biohacking peptides like BPC-157 and GLP-1 applications for mental health and addiction. Ricks contrasts unproven consumer biohacking with formal clinical trials showing massive reductions in pre-diabetes conversion and upcoming trials for bipolar disorder. | |
| MAHA Movement, Food System Reform & Public Health | 5 | 5 | 3 | 6 | Calacanis confronts Ricks with a sharp question on whether pharmaceutical companies buy off news networks through massive TV advertising budgets. Ricks subverts the host's premise by agreeing that drug TV ads should be reduced, explaining how outdated print regulations ruined TV ad quality. | |
| Patient Research Empowerment & AI/LLM Medical Accuracy | 5 | 6 | 2 | 3 | Ricks endorses patients using LLMs like ChatGPT for health research. When Friedberg asks about proposed NIH budget cuts, Ricks provides a detailed critique of the efficiency and back-scratching politics inherent in $40B worth of extramural university grants. | |
| Pharmacy Benefit Managers & Healthcare System Friction | 4 | 6 | 1 | 2 | Chamath asks about Pharmacy Benefit Managers (PBMs). Ricks breaks down how PBMs transitioned from useful 1990s claims-adjudication tech into rent-seeking middleman friction, predicting brain diseases as the next major therapeutic frontier. |
Statements from this episode (37)
Eli Lilly CEO: Tirzepatide surpassed Keytruda as best-selling drug ever
“And then terzepatide, which you asked how much money we're making, but in, actually in Q-two, we reported global sales, which surpassed Keytruda to becoming the best-selling drug in the world, actually the best-selling drug in the world of all time.”
Dave Ricks estimates 20M people globally take prescription GLP-1 drugs
“I'd estimate around twenty million take prescription GLP-I's.”
Eli Lilly has over 100 clinical studies underway for tirzepatide
“We currently have over a hundred clinical studies with the medicine going on for all kinds of other uses as well, not just slowing you down.”
Chamath Palihapitiya: Active Chinese gray market is synthesizing GLP-1 equivalents
“There is a very active gray market, particularly in China, peptide synthesis that are producing drugs that are basically the equivalent of your drug.”
Dave Ricks: Poor US insurance coverage drives patients to gray market GLP-1s
“We're not used to it in the United States. Because we, one, have a, for most people, a pretty good system to subsidize some of the benefit via the insurance markets, so there's not a lot of incentive to go outside the system. That's different for these drugs, …”
Dave Ricks says Eli Lilly's GLP-1 weight-loss pill launches in 2026
“Yeah, that's ours. Coming next year.”
Eli Lilly reduced out-of-pocket GLP-1 medication costs to $499
“We've led in reducing the out-of-pocket costs, but from, it was originally a thousand dollars, now it's four 99 from us.”
Eli Lilly expects single-digit annual GLP-1 price deflation over time
“We've told the street, expect single digit deflation in this category over time.”
Eli Lilly spends $14.2 billion on R&D, equal to 25% of sales
“We spent 25% of sales on R&D. This year that'll be 14.2 billion dollars.”
Dave Ricks: Pharma companies lack enduring franchises due to patent cliffs
“In pharma, all our, we have no enduring franchise. Everything we make goes to zero because of the patent system.”
Dave Ricks predicts Mounjaro revenues will drop to zero in the 2030s
“So, in 20, 30 something, Manjaro will go to zero.”
Eli Lilly employs 4,200 PhD scientists, matching MIT and Harvard combined
“We currently have about 4200 PhD scientists at Lilly. By the way, it's about the same as MIT and Harvard combined.”
Eli Lilly CEO Dave Ricks says biotech venture capital is totally broken
“We can talk about venture and biotech in a second because it's totally broken.”
Eli Lilly is building six US plants and announcing four more
“We're currently constructing six plants. We're going to announce four more in the next six months.”
Eli Lilly's US expansion creates over 25,000 construction and manufacturing jobs
“So yeah, this is creating 20,000 construction jobs in this period, and ultimately five or 6000 manufacturing jobs.”
Dave Ricks: Competitors cannot match our manufacturing scale without Chinese state backing
“And unless some Chinese state-owned enterprise gets in this business, it'll be very hard for others to build that out and follow.”
Eli Lilly completes an external acquisition or partnership roughly every two weeks
“We're doing a deal about every two weeks.”
Dave Ricks: Annual biotech venture funding collapsed from $20B to $5B
“Peak got to about twenty billion in new checks a year into biotech. We're now about five.”
Dave Ricks: Half of public biotech companies trade at or below cash
“Half of biotech that's publicly traded is trading at or below cash.”
Dave Ricks: Chinese entities use AI to reverse-engineer and hack chemical patents
“China's getting very good at patent hacking. So what they do is they look at that chemical structure. They work backwards, sometimes driven by AI. Algorithms define chemical structures that will behave similarly, but are outside the patent scope, and they go f…”
Dave Ricks: China's derivative biotech market significantly hurts global sector valuations
“So they're really quite a derivative biotech market, but that is also hurting biotech valuations in a significant way.”
Dave Ricks predicts competitor's GLP-1 dementia study likely won't be positive
“Our competitor is going to read out a study in a few months on dementia risk. It probably won't be positive. That's my guess, but it will probably be in the right direction.”
Dave Ricks: Low-dose GLP-1s could eventually be used to extend healthspan
“I think we're going to get to a point. We're taking pretty low doses for most people, say over 60, 58. It's not a terrible idea. It may help you live longer.”
Eli Lilly's Mounjaro demonstrated a 93% reduction in pre-diabetes conversion
“So we did that with Manjaro and showed a 93% reduction in conversion from pre-diabetes to diabetes.”
Eli Lilly is starting trials for a brain-focused GLP-1 targeting mental health
“So we are now, right now, starting studies in bipolar disorder and major depressive disorder, along with these addictive hedonic pathways where you're sort of self-medicating and with a new GLP one, a different one, that probably, that has a little less weight…”
Dave Ricks expects to launch a mental health GLP-1 in 3-4 years
“So we'll get that drug in three or four years if it works, and I think it could really change some of these terrible mental health conditions.”
Dave Ricks: The US is the least metabolically healthy large country
“I think we are the least healthy metabolic big country, and probably the reason for that is the food we feed ourselves.”
Dave Ricks claims anti-fat, high-carb diets drove US obesity growth
“The anti-fat, high-carb diets, which we were feeding people for 30 years, and I think most people don't believe in that anymore, but it led to a big part of the obesity curve, glycemic index kind of thing.”
Dave Ricks supports reducing direct-to-consumer pharmaceutical advertising
“Well, I would be for a system where we don't have nearly as much drug advertising, to be clear.”
Eli Lilly spends over half its consumer advertising budget outside TV
“By the way, more than half of our consumer spending to reach consumers is not on TV.”
Dave Ricks: Most primary care doctors are too busy to stay updated
“Most primary care doctors are way too busy to even attend a continuing education, even know what's happening.”
Dave Ricks personally uses AI models to audit information on his drugs
“I do do it myself. I also do it just to see what the different models are producing about our drugs.”
Dave Ricks: AI drug information is mostly accurate and substantially improved
“Mostly it's accurate, and they've It's gotten better over the last two years. I'd say substantially better.”
Eli Lilly is transitioning its employee prescription coverage to a transparent PBM
“Actually, our company is moving to one.”
Dave Ricks: Consolidated pharmacy benefit managers make every decision for self-enrichment
“What happened is, you know, the, like any consolidated terminal state of an industry, what's the term, the in-ification of their service, is they just become so, every, every action they make is about their benefit, not the customer.”